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An Update on the Role of Ploidy in Prostate Carcinoma 
Jill M. Peters-Gee, MD 
One ofthe characteristic features of prostate carcinoma is its marked variation in biologic behavior. 
DNA quantitation has heen studied in prostate carcinoma using a variety of techniques. Evaluaticm of 
tumor ploidy suggests that this may be the best predictor ofthe biologic behavior of prostate cancer in 
individual patients. This comprehensive review addresses the current studies, stage by stage, to 
clarify the clinical significance ofthese findings. (Henry Ford Hosp MedJ 1992;40:99-102) 
Prostate adenocarcinoma exhibits marked biologic variabil-ity (1). Response to treatment, time to progression, and ulti-
mate survival atl vary, independent of stage or grade (2). Histo-
logic grade and pathologic stage are the chief parameters cur-
rentiy used to determine individual therapy (3). While useful in 
poorly and well-differentiated tumors, these parameters have 
less prognostic significance in moderately differentiated tumors 
which comprise the largest group of patients with prostate carci-
noma. The ability to predict prognosis accurately in individual 
patients continues to elude practicing urologists. For this reason, 
we continue to look for a reliable means of predicting prognosis 
in patients with prostate carcinoma. 
It is well known that chromosomal abenations are associated 
with neoplastic transformation (4), Chromosomal changes, 
which are often nonspecific, may result in measurable increases 
in the DNA content of nuclei (5). The normal human somatic 
cell contains 46 chromosomes (23 pairs) and is referred to as 
diploid. A cell with an identifiable deviation from 46 normal 
chromosomes is described as aneuploid and may include dele-
tions, translocations, or duplications of an entire chromosome or 
portion of a chromosome. 
Nuclear DNA content or ploidy, as well as changes in cell cy-
cle kinetics, have been found to conelate with the biologic be-
havior of other tumors (6). One of the challenges in prostate car-
cinoma is to find either morphologic or biologic changes that 
can be useful predictors of disease progression. This informa-
tion, if available at the time of diagnosis, can be used clinically 
to assist in therapeutic planning and to assess the need for ad-
juvant therapy posttreatment. Much of the information used cur-
rently (i.e., lymph node status, seminal vesicle or capsular pen-
etration by tumor) is obtained with excisional therapy and 
pathologic staging (7). While it is becoming increasingly ac-
cepted that ploidy is a valuable prognostic determinate in pros-
tate cancer, its role in patient management has yet to be defined. 
Ploidy determination may be useful in selecting patients not 
suitable for conservative therapy. Further clinical decisions 
must take into account many other factors such as patient age 
and tumor grade and stage. These decisions are made on an indi-
vidual basis, taking into account all we know about the biology 
of prostate cancer. 
Techniques Available to Measure Ploidy 
Nuclear DNA quantitation and analysis of cell cycle kinetics 
have given us insight into the biology of prostate carcinoma. In-
formation about nuclear DNA changes can be obtained by tu-
mor cell chromosomal analysis, computer-assisted image analy-
sis, or flow cytometry (6). Each of these techniques has techni-
cal limitations and advantages. 
Chromosomal analysis 
Specific chromosomal changes can be measured using cyto-
genetic analysis of tumor celts. Such studies require that the tu-
mor be disaggregated either enzymatically or mechanically. The 
resulting suspension is exposed to a mitotic inhibitor and the 
cells are swelled in a hypotonic solution, fixed and spread on 
glass slides. Specific staining techniques allow characteristic 
bands to be identified in the metaphase chromosomes (8). While 
chromosomal analysis is applicable to leukemias, in solid tu-
mors such analysis is difficult with interpretable chromosome 
spreads obtained in only 10% to 20% of cases (9). Thus, techni-
cal problems preclude the use of chromosomal analysis of pros-
tate carcinoma on a routine basis. 
Computer-assisted image analysis 
Identification of individual chromosomes is possible only 
during metaphase. Nuclear DNA quantitation can be deter-
mined on interphase cells, independent of the proliferative ac-
tivity of the tumor (10). Quantitation to detect measurable in-
creases in nuclear DNA can be performed by either flow cytom-
etry or slide cytophotometry. Slide cytophotometry involves 
computer-assisted image analysis of individual cells identified 
histologically as tumor or controt cells. This high-resolution 
technique quantitates DNA content of feulgen-stained nuclei. 
Because only tumor cells are analyzed, fewer cells (200-300) are 
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needed for anatysis. The DNA histograms generated are com-
pared to normal diploid cells to determine the presence of abnor-
mal DNA content or aneuploidy (11). Computer-assisted image 
analysis, which allows DNA quantitation on small tissue sam-
ples, is useful in prostate biopsies where often a small amount of 
tumor is admixed with normal cells (12). Technically, it is easy 
to prepare tissue for image analysis. Any pathology laboratory 
can prepare the slides and analysis can be done immediately, or 
the slides may be sent for commercial DNA analysis. 
Flow cytometry 
Flow cytometry is a low-resolution technique by which the 
nuclear DNA of cells in suspension can be quantitated. Cells of 
solid tumors must be disaggregated prior to flow cytometry. A 
nanow fluid stream containing the celts in suspension passes 
through a laser beam. As each cell intersects the beam, light is 
scattered. Detectors transform the light scattering into electrical 
pulses which are measured and recorded by computer. The in-
tensity of the scattering is a function of the size, shape, and 
structure of the cell. Even though the measurements obtained 
are quantitative, unless all cells are visually examined by cell 
sorting, one cannot be certain which cell generated the signal. 
Prostate cancer samples usually contain a mixture of tumor, 
stromal, inflammatory, and hyperplastic cells. This lack of spec-
ificity is offset by the large number of cells that can be examined 
and the rapidity with which it can be performed. Most flow cy-
tometers can measure 5,000 to 10,000 cells/second. The mea-
surement is objective with no user bias introduced, in that all 
cells are analyzed. Not only can flow cytometry quantitate nu-
clear DNA, but other parameters such as cell size, volume, and 
nuclear roundness can be measured (13). 
Flow cytometry is a rapid and objective means of quantitating 
DNA. Because all cells are measured, aneuploid tumor cells 
may be diluted if only a few are admixed with normal glandular 
cells and stroma. Thus, studies by flow cytometry may underes-
timate the ploidy in tumor celts. 
Clinical Applications 
DNA ploidy was first found to be conelated with prostate 
cancer outcome in early studies using microspectrophotometry 
(14). Subsequent studies using computer-assisted image analy-
sis confirmed these early studies (15-18). Ploidy was found to 
conelate with tumor grade; well-differentiated tumors are pri-
marily diploid, and poorly differentiated tumors are primarily 
aneuploid (19,20). Early studies suggested that response to 
hormonal therapy was improved in diploid patients when com-
pared to an aneuploid group (14). Ronstrum et al (21) deter-
mined ploidy by using flow cytometry on 500 patients with ei-
ther benign prostatic hypertrophy (BPH) or prostate carcinoma. 
Aneuploidy was found in 73% of prostate carcinomas compared 
to only 8% of BPH samples (21). These studies suggest that 
ploidy may be a useful prognostic indicator for prostate carci-
noma. 
The ability to quantitate DNA on paraffin-embedded archival 
specimens allows retrospective studies to be performed on pa-
tients with known outcomes, using both image analysis and 
flow cytometry (22). These studies are discussed according to 
stage to allow for easier comparison of results and clinical appli-
cation. 
Idealized prostate carcinoma 
Approximately 9% of stage At and 36% of stage A2 tumors 
will progress. Using flow cytometry, Mctntire et al (23) demon-
strated that 67% of aneuploid stage A2 tumors progressed while 
none of diploid stage A1 tumors progressed, tn addition, Epstein 
et al (24) found that nuclear roundness was a significant predic-
tor of prognosis in untreated stage A l or A2 patients. 
Many studies have looked at stage B tumors. Montgomery et 
al (25) analyzed with flow cytometry the tumors of 283 patients 
removed by radical prostatectomy. DNA quantitation revealed 
68% diploid, 28% tetraploid, and 4% aneuploid. Overall, 20% 
progressed during a mean follow-up of 9.4 years. All of the 
aneuploid tumors progressed. Using image analysis on patients 
treated with t'-^ implantation, we have shown comparable re-
sults; 11 % of stage A or B patients were aneuploid and 89% dip-
loid. Progression to stage D2 disease occurred in 27% of pa-
tients, 80% of whom were aneuploid and 20% diploid. The dif-
ference is highly significant (P < 0.0001) (26). These studies in-
dicate that the small percentage of stage A or B patients having 
aneuploid tumors accounts for most of the disease progression. 
Several investigators have studied tumors removed by radical 
prostatectomy to determine if ploidy is useful in predicting ad-
vanced pathologic stage from capsular invasion, lymph node 
metastasis, or seminal vesicle invasion (27-29). Ritchie et al 
(29) followed 109 patients for a mean of 60.7 months after radi-
cal prostatectomy. Tumor grade was the most important deter-
minant of time to disease recunence, Ploidy did not conelate ei-
ther with grade or anatomical extent of disease Only six patients 
were aneuploid and none had recunence; however, only three 
were followed for more than three years. Lee et al (30) assessed 
88 radical prostatectomy patients similarly. In this series 
aneuploidy, Gleason grade, and seminal vesicle involvement all 
conelated significantly with disease recunence. Aneuploidy 
was found in 58% of patients (68% with seminal vesicle in-
volvement compared to 38% without seminal vesicle involve-
ment). 
A subsequent study revealed a strong association between 
DNA ploidy and serum prostate-specific antigen (PSA) levels 
preoperatively (31). All patients with an aneuploid or tetraploid 
tumor had elevated PSA, and all patients with a PSA less than 
4.0 ng/mL were diploid. These data suggest that if ploidy is in 
fact a useful predictor of the biologic behavior of prostate cancer 
in an individual patient, PSA may be a useful predictor of ploidy 
in localized disease. However, PSA is related to tumor volume, 
and ploidy may also be related to the volume of tumor present. 
This question was addressed by Jones et al (32) who studied 57 
patients who had undergone radical prostatectomy. They com-
pared ploidy (determined by flow cytometry) to tumor volume, 
lymph node status, and histologic grade. All aneuploid tumors. 
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which were found in 46% of patients, were greater than 4 mL in 
volume with only one exception. Because there was an overiap 
in behavior of diploid and aneuploid tumors, Jones et al (32) 
concluded that ploidy could not be used as an independent pre-
dictor to direct preoperative treatment. Thus, while many stud-
ies support the use of ploidy as a prognostic determinant, its 
clinical usefulness is still debated. 
Stage C prostate carcinoma 
Ploidy has been reported to be a useful predictor of disease 
progression in stage C tumors. Lee et al (30) found that patients 
with stage C diploid tumors had an 85% chance of remaining 
disease-free for 5 years, compared to only 9% with aneuploid 
DNA. In a larger series of 146 patients with stage C tumors 
treated by radical prostatectomy, Nativ et al (33) found that the 
median time to progression was 3.5 years in the aneuploid group 
compared to 7.4 years in the diploid or tetraploid patients. Stage 
C patients with low-grade diploid tumors have a progression-
free survival of 92% at 10 years, compared to 57% for patients 
with low-grade nondiploid tumors. However, other investiga-
tors have not been able to confirm these findings (34,35). 
Stage D prostate carcinoma 
Patients with stage Dl prostate carcinoma are a clinical chal-
lenge. The role and timing of adjuvant therapy is still debated 
(36). Using image analysis in this group of patients, we have 
found a significant difference in time to progression of disease 
in aneuploid patients compared to diploid patients (median time 
37.2 months versus 76.9 months, respectively) (36). This study 
using image analysis assessed ploidy in the lymph node metas-
tases. Stephenson et al (37), using flow cytometry to assess 
ploidy in lymph node metastases, found a median survival of 8.8 
years for diploid patients compared to 5 years for the aneuploid 
group. 
Using flow cytometry on the primary tumor, Winkler et at 
(38) demonstrated 13% aneuploid tumors. Only 15% of the 
DNA diploid tumors progressed locally or systemically com-
pared to 75% of tetraploid or aneuploid tumors (38). These stud-
ies indicate that ploidy is a significant predictor of progression 
and/or survival. How this will impact clinical decision-making 
is not yet clear. 
Summary 
Analysis of tumor ploidy may be a significant prognostic de-
terminant providing insight into the biologic behavior of the 
prostate cancer in individual patients. Available data demon-
strate marked variability in tumor ploidy, which may be due to 
differing techniques of DNA quantitation and variability in the 
definition of aneuploidy. Before clinical decisions can be made 
based on ploidy, one must know the predictive value, sensitiv-
ity, and specificity of the technique being used. There is much 
debate conceming the heterogeneity of prostate cancer. It is pos-
sible that ploidy varies throughout the tumor. Sampling enor 
may be part of the reason variability exists in ploidy measure-
ments found in different studies. Prospective studies and contin-
ued improvement in techniques for DNA analysis are necessary 
before precise recommendations can be made conceming clini-
cal use of the data. Research centers utilizing ploidy determina-
tion in clinical decision-making should clarify this issue. 
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